Strontium ranelate for the treatment of osteoporosis

British Medical Journal

Volumn 330, Issue 7505, 2005, Pages 1400-1401

  Fogelman, Ignac ^a   Blake, Glen M ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; FLUORIDE; PARATHYROID HORMONE[1-34]; STRONTIUM RANELATE;

BONE DENSITOMETRY; BONE DENSITY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; FRAGILITY FRACTURE; HUMAN; NAUSEA; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL;

EID: 21044443289     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.330.7505.1400     Document Type: Editorial

References (12)

1. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Summary of meta-analyses of therapies for postmenopausal osteporosis. Endocrine Rev 2002;23:570-8.
2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
3. Cummings SR, Black DM, Thompson DE, Applegale WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 1998;280:2077-82.
4. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282: 1344-52.
5. McClung MR, Gensens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate treatment on hip fracture risk in elderly women. N Engl J Med 2001;344:333-40.
6. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, et al. Effect of parathyroid hormone (I-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-41.
7. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350: 459-68.
8. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TROPOS study. J Clin Endocrinol Metab 2005. (Published online 22 Feb; doi:10.1210/jc.2004-1774.)
9. Marshall JH, Lloyd EL, Rundo J, Liniecki J, Marotti G, Mays CW, et al. Alkaline earth metabolism in adult man. A report prepared by a task group of committee 2 of the International Commission on Radiological Protection (ICRP publication 20). Health Phys 1973;24:129-221.
10. Boivin G, Deloffre P, Perrat B, Panczer G, Boudeulle M, Mauras Y, et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt administration (S12911). J Bone Miner Res 1996;11:1302-11.
11. Pors Nielsen S, Slosman D, Sorensen OH, Basse-Cathelinat B, De Casin P, Roux C, et al. Influence of strontium on bone mineral density and bone mineral content measurements by dual x-ray absorptiometry. J Clin Densitom 1999;2:371-9.
12. Riggs BL, Hodgson SF, O'Fallan M, Chao EYS, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-9.